The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8,785.00
Bid: 8,780.00
Ask: 8,790.00
Change: 0.00 (0.00%)
Spread: 10.00 (0.114%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 8,785.00
SPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

21 Nov 2017 07:00

RNS Number : 0224X
Spirax-Sarco Engineering PLC
21 November 2017
 

 

 

News Release

 

Tuesday 21st November 2017

TRADING UPDATE

Underlying markets remain positive, overall expectations unchanged

 

Spirax-Sarco Engineering plc, the world leader in the control and efficient use of steam, electrical thermal energy solutions and peristaltic pumping and associated fluid path technologies, issues the following trading update in respect of the period ended 31st October 2017.

 

Economic Environment

The global macro-economic environment for the Group remains positive with the latest forecast for Global Industrial Production (IP) growth for 2017 being 3.5%, marginally above the 3.3% forecast at the time of our Interim Report. As in the first half, growth is skewed towards the emerging economies where the increase is forecast to be 5.0%, compared with 2.5% in the developed economies, with much of the differential coming from strong growth in China.

 

Trading

As anticipated, Group organic* sales growth in the four months to October increased modestly from that achieved in the first half of the year, reflecting the generally positive industrial backdrop.

 

In EMEA, organic sales growth in the four months to October was higher than in the first half of the year with the segment benefitting from a strong order book at the beginning of the second half of the year and improved underlying markets. Organic growth in Asia Pacific has continued to be strong with good performance in China and Korea, our two largest territories in the region. In the Americas, however, organic growth has continued to be difficult to find and performance was only marginally ahead of that seen in the first half of the year. Growth in the Watson-Marlow Fluid Technology Group continues to be strong, in line with that seen in the first half of the year.

 

Hiter and Aflex which were acquired in 2016 and Gestra and Chromalox which joined the Group this year are all progressing well and are performing in line with expectations. To date we have had a positive response from the customers and employees of these businesses and their integration is proceeding as planned. In particular, we were pleased that the relatively complex carve-out of some of the Gestra businesses from their previous parent were completed on schedule at the end of September. The net effect of these acquisitions is anticipated to increase the full-year sales by approximately 19%.

 

As at the half year, Group operating profit is ahead of the comparable ten-month period at constant currency, both on an organic basis and when the effects of the above acquisitions are included.

 

Following the anniversary of the Brexit vote in June this year, currency effects have moderated. If spot rates at 31st October 2017 prevail to the end of 2017, sales for the full year would be increased by approximately 5% with the uplift in profits expected to be in the region of 8%.

 

If October's foreign exchange rates continue into next year we would expect to see a reduction in sales and profits in 2018 due to currency movements of just under 2% and 3% respectively.

 

Financial position

Our business remains highly cash generative and we maintain a strong balance sheet. The Group financed the acquisitions of Gestra in May and Chromalox in July from existing cash resources and new debt facilities. At 31st October 2017 the net borrowings of the Group were £379 million. The interim dividend for 2017 of 25.5p per share was paid on 10th November at a cash cost of £19 million.

 

In line with the increased level of debt, interest costs will increase and in total (cash and pension) are expected to be in the region of £7 million for the year.

 

Outlook

Industrial production growth rates are forecast to remain positive for the remainder of the year in both developed and emerging markets although predictions for 2018 are less clear, particularly with regard to China. We continue with our investment programmes in support of future growth and the implementation of our strategy to generate growth from our own actions to outperform our markets. We achieve this by being more effective in identifying and generating engineered solutions to help our customers with energy efficiency, sustainability, productivity, quality, cost reduction and compliance with ever increasing regulatory requirements.

 

Whilst, as always, we have limited visibility due to the short-term nature of our order book, we have good diversification across market sectors and geographic regions and remain focused on our strategies for growth, which, together with the Group's fundamental strengths, stand us in good stead. We still have much to do in the remainder of this year but our overall expectations for the full-year are unchanged and the Board has confidence that the Group will make further progress in 2017.

 

Spirax Sarco expects to publish its preliminary 2017 results on 15th March 2018.

 

Enquiries:

Nicholas Anderson, Group Chief Executive

Kevin Boyd, Group Finance Director

Tel: 01242 535234

 

Note: References to profit are to adjusted profit that excludes the amortisation and impairment of acquisition-related intangible assets and acquisition and disposal costs, together with the tax effects of these items.

* References to organic changes are excluding acquisitions and disposals, and are expressed at constant currency.

 

About Spirax Sarco

Spirax-Sarco Engineering plc comprises two world-leading businesses, Spirax Sarco for steam and electrical thermal energy solutions and Watson-Marlow Fluid Technology Group for niche peristaltic pumps and associated fluid path technologies. Spirax Sarco provides a broad range of fluid control and electrical process heating products, engineered packages, site services and systems expertise for a diverse range of industrial and institutional customers. The business helps its end users to improve production efficiency, reduce energy costs, water usage and emissions, improve product quality and enhance the safety of their operations. Watson-Marlow Fluid Technology Group offers the ideal solution for a wide variety of demanding fluid path applications with highly accurate, controllable and virtually maintenance free pumps and associated technologies. The Group is headquartered in Cheltenham, England, has strategically located manufacturing plants around the world and employs over 7,000 people, of whom approximately 1,550 are direct sales and service engineers. Its shares have been listed on the London Stock Exchange since 1959 (symbol: SPX).

 Further information can be found at www.spiraxsarcoengineering.com 

 RNS filter: Inside information prior to release

 

LEI 213800WFVZQMHOZP2W17

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQBLFLDFFZFBQ
Date   Source Headline
10th Apr 20244:44 pmRNSDirector/PDMR Shareholding
26th Mar 20249:33 amRNSDirector/PDMR Shareholding
20th Mar 202410:00 amRNSDirector/PDMR Shareholding
18th Mar 20242:34 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNS2023 Full Year Results
22nd Feb 20247:00 amRNSSpirax-Sarco Engineering rebrands as Spirax Group
1st Feb 20243:38 pmRNSChange of Director Details
30th Jan 202411:15 amRNSFuture Board Change
17th Jan 20247:00 amRNSLeadership Succession
18th Dec 20237:00 amRNSChief Financial Officer Appointment
21st Nov 20239:15 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSDirector/PDMR Shareholding
20th Nov 20237:00 amRNSShare Purchases
16th Nov 20237:00 amRNSTrading Update
11th Oct 20238:40 amRNSDirector/PDMR Shareholding
25th Aug 20239:30 amRNSHolding(s) in Company
25th Aug 20238:30 amRNSHolding(s) in Company
10th Aug 20237:00 amRNS2023 Half Year Results
8th Aug 20237:00 amRNSGroup Chief Executive Succession
2nd Aug 20238:00 amRNSBoard Appointment
1st Aug 20239:09 amRNSDirector/PDMR Shareholding
27th Jul 20239:30 amRNSChange in Director Details
26th Jun 202310:00 amRNSNotice of Investment Seminar
22nd Jun 20232:03 pmRNSHolding(s) in Company
22nd Jun 20237:00 amRNSKyoto Investment and Partnership Agreement
14th Jun 202310:42 amRNSHolding(s) in Company
9th Jun 20235:45 pmRNSHolding(s) in Company
24th May 20232:46 pmRNSHolding(s) in Company
10th May 20233:23 pmRNSResult of AGM
10th May 20237:00 amRNSAGM Trading Update
16th Mar 20234:22 pmRNSDirector/PDMR Shareholding
16th Mar 20239:00 amRNSDirector/PDMR Shareholding
15th Mar 20234:12 pmRNSDirector/PDMR Shareholding
15th Mar 20239:53 amRNSDirector/PDMR Shareholding
15th Mar 20239:48 amRNSHolding(s) in Company
13th Mar 20231:31 pmRNSDirector/PDMR Shareholding
13th Mar 202312:22 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20233:09 pmRNSChange of Director Details
21st Feb 202310:32 amRNSHolding(s) in Company
31st Jan 20239:30 amRNSBoard Changes
30th Jan 20236:04 pmRNSHolding(s) in Company
23rd Dec 202210:31 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSCompletion of the Acquisition of Durex Industries
17th Nov 20227:00 amRNSTrading Statement
27th Oct 20224:24 pmRNSDirector/PDMR Shareholding
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20227:00 amRNSCompletion of the acquisition of Vulcanic
28th Sep 20227:00 amRNSAcquisition of US Thermal Energy Specialist
6th Sep 202212:41 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.